RxDoctor Payments Data

Erin Erbskorn, NP

Family · Little Elm, TXNPI 1194495390

Payments from drug & device makers

$1,116in general payments, 2019–2025

Across 57 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$267
  • AstraZeneca$202
  • AbbVie$200
  • Lilly USA, LLC$88
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$82
  • Boehringer Ingelheim$73
  • plus $205 from 6 others

What the payments were for

  • Food & beverage$1,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,116 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$1,567
Medicare patients
12
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$25,794
JardianceEmpagliflozin18$21,693
EliquisApixaban20$18,342
OzempicSemaglutide18$17,815
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,090
Tresiba Flextouch U-100Insulin Degludec13$5,622
Levothyroxine Sodium162$1,580
Gabapentin57$800
Omeprazole40$750
Atorvastatin Calcium104$741
Rosuvastatin Calcium74$736
Clorazepate Dipotassium15$731
Tramadol Hcl42$617
Lisinopril97$545
Estradiol17$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$88$25,79425 claims
Boehringer IngelheimJardiance$73$21,69318 claims
Novo NordiskOzempic$60$17,81518 claims
AbbVieSynthroid$200$47614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Little Elm

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →